Oncogenic BRAF Alterations and Their Role in Brain Tumors

Alterations of the v-raf murine sarcoma viral oncogene homolog B (BRAF) have been extensively studied in several tumor entities and are known to drive cell growth in several tumor entities. Effective targeted therapies with mutation-specific small molecule inhibitors have been developed and establis...

Full description

Bibliographic Details
Main Authors: Felix Behling, Jens Schittenhelm
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/11/6/794
id doaj-62b0caac3ce14ce785a17481f2911df1
record_format Article
spelling doaj-62b0caac3ce14ce785a17481f2911df12020-11-25T01:52:00ZengMDPI AGCancers2072-66942019-06-0111679410.3390/cancers11060794cancers11060794Oncogenic BRAF Alterations and Their Role in Brain TumorsFelix Behling0Jens Schittenhelm1Department of Neurosurgery, Eberhard Karls University Tübingen, 72074 Tübingen, GermanyDepartment of Neuropathology, Comprehensive Cancer Center Tübingen-Stuttgart and Eberhard Karls University Tübingen, Abt. für Neuropathologie, Calwer Str.3, 72074 Tübingen, GermanyAlterations of the v-raf murine sarcoma viral oncogene homolog B (BRAF) have been extensively studied in several tumor entities and are known to drive cell growth in several tumor entities. Effective targeted therapies with mutation-specific small molecule inhibitors have been developed and established for metastasized malignant melanoma. The BRAF V600E mutation and KIAA1549-BRAF fusion are alterations found in several brain tumors and show a distinct prognostic impact in some entities. Besides the diagnostic significance for the classification of central nervous system tumors, these alterations present possible therapy targets that may be exploitable for oncological treatments, as it has been established for malignant melanomas. In this review the different central nervous system tumors harboring BRAF alterations are presented and the diagnostic significance, prognostic role, and therapeutic potential are discussed.https://www.mdpi.com/2072-6694/11/6/794BRAF V600EKIAA1549-BRAFMAPKastrocytomaglioblastoma
collection DOAJ
language English
format Article
sources DOAJ
author Felix Behling
Jens Schittenhelm
spellingShingle Felix Behling
Jens Schittenhelm
Oncogenic BRAF Alterations and Their Role in Brain Tumors
Cancers
BRAF V600E
KIAA1549-BRAF
MAPK
astrocytoma
glioblastoma
author_facet Felix Behling
Jens Schittenhelm
author_sort Felix Behling
title Oncogenic BRAF Alterations and Their Role in Brain Tumors
title_short Oncogenic BRAF Alterations and Their Role in Brain Tumors
title_full Oncogenic BRAF Alterations and Their Role in Brain Tumors
title_fullStr Oncogenic BRAF Alterations and Their Role in Brain Tumors
title_full_unstemmed Oncogenic BRAF Alterations and Their Role in Brain Tumors
title_sort oncogenic braf alterations and their role in brain tumors
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2019-06-01
description Alterations of the v-raf murine sarcoma viral oncogene homolog B (BRAF) have been extensively studied in several tumor entities and are known to drive cell growth in several tumor entities. Effective targeted therapies with mutation-specific small molecule inhibitors have been developed and established for metastasized malignant melanoma. The BRAF V600E mutation and KIAA1549-BRAF fusion are alterations found in several brain tumors and show a distinct prognostic impact in some entities. Besides the diagnostic significance for the classification of central nervous system tumors, these alterations present possible therapy targets that may be exploitable for oncological treatments, as it has been established for malignant melanomas. In this review the different central nervous system tumors harboring BRAF alterations are presented and the diagnostic significance, prognostic role, and therapeutic potential are discussed.
topic BRAF V600E
KIAA1549-BRAF
MAPK
astrocytoma
glioblastoma
url https://www.mdpi.com/2072-6694/11/6/794
work_keys_str_mv AT felixbehling oncogenicbrafalterationsandtheirroleinbraintumors
AT jensschittenhelm oncogenicbrafalterationsandtheirroleinbraintumors
_version_ 1724995456645201920